Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Mol Cell Biol ; 36(16): 2168-81, 2016 08 15.
Article in English | MEDLINE | ID: mdl-27215388

ABSTRACT

A long-standing paradox in the pathophysiology of metabolic diseases is the selective insulin resistance of the liver. It is characterized by a blunted action of insulin to reduce glucose production, contributing to hyperglycemia, while de novo lipogenesis remains insulin sensitive, participating in turn to hepatic steatosis onset. The underlying molecular bases of this conundrum are not yet fully understood. Here, we established a model of selective insulin resistance in mice by silencing an inhibitor of insulin receptor catalytic activity, the growth factor receptor binding protein 14 (Grb14) in liver. Indeed, Grb14 knockdown enhanced hepatic insulin signaling but also dramatically inhibited de novo fatty acid synthesis. In the liver of obese and insulin-resistant mice, downregulation of Grb14 markedly decreased blood glucose and improved liver steatosis. Mechanistic analyses showed that upon Grb14 knockdown, the release of p62/sqstm1, a partner of Grb14, activated the transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2), which in turn repressed the lipogenic nuclear liver X receptor (LXR). Our study reveals that Grb14 acts as a new signaling node that regulates lipogenesis and modulates insulin sensitivity in the liver by acting at a crossroad between the insulin receptor and the p62-Nrf2-LXR signaling pathways.


Subject(s)
Insulin Resistance , Lipogenesis , Liver/metabolism , Proteins/genetics , Signal Transduction , Adaptor Proteins, Signal Transducing , Animals , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Gene Expression Regulation , Gene Knockdown Techniques , Liver/cytology , Liver X Receptors/metabolism , Mice , NF-E2-Related Factor 2/metabolism , Proteins/metabolism , Receptor, Insulin/metabolism
2.
PLoS One ; 11(4): e0152872, 2016.
Article in English | MEDLINE | ID: mdl-27035144

ABSTRACT

The aim of the study was to evaluate ovarian toxicity of tyrosine kinase inhibitor (TKI) sunitinib, since only scarce data are available on gonadal function after this treatment. Six-week-old female mice received orally, once daily, vehicle or sunitinib (50 mg/kg/d) during 5 weeks. Fertility parameters were analyzed from ovulation to litter assessment. Sunitinib exposure significantly reduced (i) corpora lutea number per ovary (1.1 ± 0.38 in sunitinib group versus 4 ± 0.79 in control group, p<0.01) and (ii) serum Anti Müllerian hormone (AMH) levels in sunitinib treated mice (12.01 ± 1.16) compared to control mice (14.33 ± 0.87 ng/ml, p< 0.05). However, primordial and growing follicles numbers per ovary were not different in both groups. After treatment withdrawal, female mice in both groups were able to obtain litters. These data could be helpful to counsel clinicians and patients, when fertility preservation methods are discussed, before TKI treatment in girls and young women.


Subject(s)
Antineoplastic Agents/pharmacology , Indoles/pharmacology , Ovarian Reserve/drug effects , Ovulation/drug effects , Pyrroles/pharmacology , Animals , Female , Mice , Protein-Tyrosine Kinases/antagonists & inhibitors , Sunitinib
3.
Cell Signal ; 27(4): 798-806, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25578860

ABSTRACT

Beyond its key role in the control of energy metabolism, insulin is also an important regulator of cell division and neoplasia. However, the molecular events involved in insulin-driven cell proliferation are not fully elucidated. Here, we show that the ubiquitin ligase Chfr, a checkpoint protein involved in G2/M transition, is a new effector involved in the control of insulin-induced cell proliferation. Chfr is identified as a partner of the molecular adapter Grb14, an inhibitor of insulin signalling. Using mammalian cell lines and the Xenopus oocyte as a model of G2/M transition, we demonstrate that Chfr potentiates the inhibitory effect of Grb14 on insulin-induced cell division. Insulin stimulates Chfr binding to the T220 residue of Grb14. Both Chfr binding site and Grb14 C-ter BPS-SH2 domain, mediating IR binding and inhibition, are required to prevent insulin-induced cell division. Targeted mutagenesis revealed that Chfr ligase activity and phosphorylation of its T39 residue, a target of Akt, are required to potentiate Grb14 inhibitory activity. In the presence of insulin, the binding of Chfr to Grb14 activates its ligase activity, leading to Aurora A and Polo-like kinase degradation and blocking cell division. Collectively, our results show that Chfr and Grb14 collaborate in a negative feedback loop controlling insulin-stimulated cell division.


Subject(s)
Cell Proliferation , Insulin/metabolism , Proteins/metabolism , Ubiquitin-Protein Ligases/metabolism , Adaptor Proteins, Signal Transducing , Animals , Binding Sites , COS Cells , Cell Cycle , Cell Cycle Proteins/metabolism , Cell Line , Chlorocebus aethiops , Gene Knockout Techniques , Mutagenesis , Poly-ADP-Ribose Binding Proteins , Protein Serine-Threonine Kinases/metabolism , Protein Structure, Tertiary , Proteins/chemistry , Proteins/genetics , Proto-Oncogene Proteins/metabolism , Rats , Signal Transduction , Ubiquitin-Protein Ligases/chemistry , Ubiquitin-Protein Ligases/genetics , Xenopus , Polo-Like Kinase 1
4.
PLoS One ; 9(3): e91422, 2014.
Article in English | MEDLINE | ID: mdl-24667351

ABSTRACT

Hyperprolactinemia occurs during gestation and lactation with marked hyperphagia associated with leptin resistance. Prolactin (PRL) induces the expression of orexigenic neuropeptide Y (NPY) in hypothalamic dorsomedial nucleus (DMH) leading to hyperphagia. Along this line prolactin receptor deficient (PRLR-/-) mice are resistant to obesity under high fat diet due to increased energy expenditure. As these mice have an altered food intake, our objective was to test whether leptin is responsible for these characteristics. PRLR-/- male mice and control littermates were injected subcutaneously every other day with 12 mg/kg pegylated superactive mouse leptin antagonist (PEG-SMLA) for 3 weeks. We tested the effect of PEG-SMLA on body weight, food intake and metabolic parameters. The antagonist led to a rapid increase in body weight (20%) but increased adipose mass in PEG-SMLA treated mice was less pronounced in PRLR-/- than in WT mice. Food intake of PEG-SMLA-injected animals increased during the first week period of the experiment but then declined to a similar level of the control animals during the second week. Interestingly, PRLR-/- mice were found to have the same bone volume than those of control mice although PEG-SMLA increased bone mass by 7% in both strains. In addition, PEG-SMLA led to insulin resistance and glucose intolerance as well as an altered lipid profile in treated mice. Altogether, these results suggest that PRLR-/- mice respond to leptin antagonist similarly to the control mice, indicating no interaction between the actions of the two hormones.


Subject(s)
Adiposity/drug effects , Insulin Resistance , Leptin/analogs & derivatives , Leptin/antagonists & inhibitors , Polyethylene Glycols/pharmacology , Receptors, Prolactin/physiology , Weight Gain/drug effects , Adiposity/genetics , Animals , Bone and Bones/drug effects , Glucose Intolerance/chemically induced , Glucose Tolerance Test , Leptin/pharmacology , Male , Mice , Mice, Knockout , Trabecular Meshwork/drug effects
5.
Biochimie ; 97: 16-21, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24120689

ABSTRACT

The pituitary lactogenic hormone prolactin (PRL) exerts various physiological actions in humans and rodents via its binding to a membrane receptor. Beside its role in lactation and reproduction, accumulating evidence suggests that PRL has a crucial impact on energy balance by acting on two key players, the pancreas and the adipose tissue. Adipose tissue is now recognized as an endocrine organ and its metabolic activity appears to play an important role in pathophysiology such as obesity and diabetes. White adipocytes store excess of energy in the form of triglycerides for future need while brown adipocytes metabolize lipids and glucose to produce heat, highlighting their different metabolic functionality. The plasticity of white adipose tissue, by the emergence of beige adipocytes, appears to be essential in energy homeostasis. PRL receptor deficient mice provided direct evidence that PRL signaling is involved in the regulation of adipogenesis affecting energy balance and metabolic adaptation most notably during development. Moreover, it was demonstrated that PRL signaling participates to brown adipose tissue differentiation and function, opening novel understanding of hormonal regulation of energy balance. This review summarizes our current knowledge about PRL signaling and its role on adipose tissue.


Subject(s)
Adipose Tissue, Brown/physiology , Adipose Tissue, White/physiology , Energy Metabolism , Prolactin/metabolism , Receptors, Prolactin/metabolism , Adipose Tissue, Brown/cytology , Adipose Tissue, White/cytology , Animals , Female , Gene Expression Regulation , Glucose/metabolism , Humans , Lipid Metabolism , Mice , Pancreas/physiology , Prolactin/genetics , Receptors, Prolactin/genetics , Signal Transduction
6.
Am J Physiol Endocrinol Metab ; 305(10): E1309-18, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24064341

ABSTRACT

Prolactin (PRL) and placental lactogens stimulate ß-cell replication and insulin production in pancreatic islets and insulinoma cells through binding to the PRL receptor (PRLR). However, the contribution of PRLR signaling to ß-cell ontogeny and function in perinatal life and the effects of the lactogens on adaptive islet growth are poorly understood. We provide evidence that expansion of ß-cell mass during both embryogenesis and the postnatal period is impaired in the PRLR(-/-) mouse model. PRLR(-/-) newborns display a 30% reduction of ß-cell mass, consistent with reduced proliferation index at E18.5. PRL stimulates leucine incorporation and S6 kinase phosphorylation in INS-1 cells, supporting a role for ß-cell mTOR signaling in PRL action. Interestingly, a defect in the development of acini is also observed in absence of PRLR signaling, with a sharp decline in cellular size in both endocrine and exocrine compartments. Of note, a decrease in levels of IGF-II, a PRL target, in the Goto-Kakizaki (GK) rat, a spontaneous model of type 2 diabetes, is associated with a lack of PRL-mediated ß-cell proliferation in embryonic pancreatic buds. Reduced pancreatic IGF-II expression in both rat and mouse models suggests that this factor may constitute a molecular link between PRL signaling and cell ontogenesis. Together, these results provide evidence that PRL signaling is essential for pancreas ontogenesis during the critical perinatal window responsible for establishing functional ß-cell reserve.


Subject(s)
Insulin-Secreting Cells/physiology , Pancreas/embryology , Prolactin/metabolism , Receptors, Prolactin/metabolism , Animals , Animals, Newborn , Cell Differentiation , Cells, Cultured , Embryo, Mammalian , Female , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/drug effects , Mice , Mice, Knockout , Pancreas/drug effects , Pancreas/growth & development , Pregnancy , Prolactin/pharmacology , Rats , Rats, Wistar , Receptors, Prolactin/genetics , Signal Transduction/drug effects , Signal Transduction/physiology
7.
Am J Physiol Endocrinol Metab ; 305(7): E845-52, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-23921141

ABSTRACT

Transgenic female mice overexpressing the hCGß subunit (hCGß(+)) and producing elevated levels of luteinizing hormone (LH)/hCG bioactivity present as young adults with enhanced ovarian steroidogenesis, precocious puberty, and infertility. They subsequently develop pituitary prolactinomas, high circulating prolactin (PRL) levels, and marked mammary gland lobuloalveolar development followed by adenocarcinomas. None of these phenotypes appear in gonadectomized mice, indicating that the hCG-induced aberrations of ovarian function are responsible for the extragonadal phenotypes. PRL receptor-deficient (PRLR(-/-)) female mice are sterile, despite ovulating, due to a failure of embryo implantation, as a consequence of decreased ovarian LH receptor (Lhcgr) expression and inadequate corpus luteum formation and progesterone production. To study further the presumed permissive role of PRL in the maintenance of gonadal responsiveness to LH/hCG stimulation, we crossed the hCGß(+) and PRLR(-/-) mice. The double-mutant hCGß(+)/PRLR(-/-) females remained sterile with an ovarian phenotype similar to PRLR(-/-) mice, indicating that LH action, Lhcgr expression, and consequent luteinization are not possible without simultaneous PRL signaling. The high frequency of pituitary prolactinomas in PRLR(-/-) mice was not affected by transgenic hCGß expression. In contrast, none of the hCGß(+)/PRLR(-/-) females showed either mammary gland lobuloalveolar development or tumors, and the increased mammary gland Wnt-5b expression, possibly responsible for the tumorigenesis in hCGß(+) mice, was absent in double-mutant mice. Hence, high LH/hCG stimulation is unable to compensate for missing PRL signaling in the maintenance of luteal function. PRL thus appears to be a major permissive regulator of LH action in the ovary and of its secondary extragonadal effects.


Subject(s)
Carcinogenesis/metabolism , Luteinizing Hormone/metabolism , Ovary/metabolism , Prolactin/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Carcinogenesis/pathology , Chorionic Gonadotropin, beta Subunit, Human/genetics , Chorionic Gonadotropin, beta Subunit, Human/metabolism , Corpus Luteum/metabolism , Female , Mammary Glands, Animal/metabolism , Mammary Glands, Animal/pathology , Mammary Neoplasms, Animal/genetics , Mammary Neoplasms, Animal/metabolism , Mammary Neoplasms, Animal/pathology , Mice , Mice, Transgenic , Progesterone/metabolism , Prolactin/blood , Receptors, Prolactin/genetics , Receptors, Prolactin/metabolism
8.
FEBS J ; 280(3): 794-816, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23190452

ABSTRACT

The effects of insulin and type 1 insulin-like growth factor (IGF-1) on metabolism, growth and survival are mediated by their association with specific receptor tyrosine kinases, which results in both receptor and substrate phosphorylation. Phosphotyrosine residues on receptors and substrates provide docking sites for signaling proteins containing SH2 (Src homology 2) domains, including molecular adaptors. This review focuses on the regulation of insulin/IGF-1 signaling and action by two adaptor families with a similar domain organization: the growth factor receptor-bound proteins Grb7/10/14 and the SH2B proteins. Both Grb10/14 and SH2B1/B2 associate with the activation loop of insulin/IGF-1 receptors through their SH2 domains, but association of Grb10/14 also involves their unique BPS domain. Consistent with Grb14 binding as a pseudosubstrate to the kinase active site, insulin/IGF-induced activation of receptors and downstream signaling pathways in cultured cells is inhibited by Grb10/14 adaptors, but is potentiated by SH2B1/B2 adaptors. Accordingly, Grb10 and Grb14 knockout mice show improved insulin/IGF sensitivity in vivo, and, for Grb10, overgrowth and increased skeketal muscle and pancreatic ß-cell mass. Conversely, SH2B1-depleted mice display insulin and IGF-1 resistance, with peripheral depletion leading to reduced adiposity and neuronal depletion leading to obesity through associated leptin resistance. Grb10/14 and SH2B1 adaptors also modulate insulin/IGF-1 action by interacting with signaling components downstream of receptors and exert several tissue-specific effects. The identification of Grb10/14 and SH2B1 as physiological regulators of insulin signaling and action, together with observations that variants at their gene loci are associated with obesity and/or insulin resistance, highlight them as potential therapeutic targets for these conditions.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Adaptor Proteins, Vesicular Transport/metabolism , GRB10 Adaptor Protein/metabolism , Receptor, IGF Type 1/metabolism , Receptor, Insulin/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Vesicular Transport/genetics , Animals , Binding Sites/genetics , GRB10 Adaptor Protein/genetics , Humans , Models, Biological , Receptor, IGF Type 1/genetics , Receptor, Insulin/genetics
9.
J Clin Invest ; 122(10): 3791-5, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23006326

ABSTRACT

Hyperprolactinemia is the most common cause of hypogonadotropic anovulation and is one of the leading causes of infertility in women aged 25-34. Hyperprolactinemia has been proposed to block ovulation through inhibition of GnRH release. Kisspeptin neurons, which express prolactin receptors, were recently identified as major regulators of GnRH neurons. To mimic the human pathology of anovulation, we continuously infused female mice with prolactin. Our studies demonstrated that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin secretion, and diminished kisspeptin expression. Kisspeptin administration restored gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a major role in hyperprolactinemic anovulation. Our studies indicate that administration of kisspeptin may serve as an alternative therapeutic approach to restore the fertility of hyperprolactinemic women who are resistant or intolerant to dopamine agonists.


Subject(s)
Anovulation/drug therapy , Hyperprolactinemia/drug therapy , Kisspeptins/therapeutic use , Animals , Anovulation/etiology , Anovulation/physiopathology , Disease Models, Animal , Drug Evaluation, Preclinical , Estrous Cycle/drug effects , Female , Gene Expression Regulation/drug effects , Gonadotropin-Releasing Hormone/metabolism , Gonadotropins, Pituitary/biosynthesis , Gonadotropins, Pituitary/blood , Gonadotropins, Pituitary/metabolism , Hyperprolactinemia/chemically induced , Hyperprolactinemia/complications , Hyperprolactinemia/physiopathology , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/physiology , Hypothalamus/drug effects , Hypothalamus/metabolism , Infusion Pumps, Implantable , Kisspeptins/biosynthesis , Kisspeptins/genetics , Male , Mice , Prolactin/administration & dosage , Prolactin/toxicity , Pulsatile Flow , RNA, Messenger/biosynthesis , RNA, Messenger/genetics
10.
FASEB J ; 26(9): 3728-37, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22637534

ABSTRACT

Stimulating conversion of white fat to metabolically active adipocytes (beige fat) constitutes a promising strategy against weight gain and its deleterious associated-disorders. We provide direct evidence that prolactin (PRL), best known for its actions on the mammary gland, plays a pivotal role in energy balance through the control of adipocyte differentiation and fate. Here we show that lack of prolactin receptor (PRLR) causes resistance to high-fat-diet-induced obesity due to enhanced energy expenditure and increased metabolic rate. Mutant mice displayed reduced fat mass associated with appearance of massive brown-like adipocyte foci in perirenal and subcutaneous but not in gonadal fat depots under a high-fat diet. Positron emission tomography imaging further demonstrated the occurrence of these thermogenic brown fat depots in adult mice, providing additional support for recruitable brown-like adipocytes (beigeing) in white fat depots. Consistent with the activation of brown adipose tissue, PRLR inactivation increases expression of master genes controlling brown adipocyte fate (PRDM16) and mitochondrial function (PGC1α, UCP1). Altered pRb/Foxc2 expression suggests that this PRL-regulated pathway may contribute to beige cell commitment. Together, these results provide direct genetic evidence that PRLR affects energy balance and metabolic adaptation in rodents via effects on brown adipose tissue differentiation and function.


Subject(s)
Adipose Tissue, Brown/cytology , Cell Differentiation , Dietary Fats/administration & dosage , Obesity/prevention & control , Receptors, Prolactin/metabolism , Adipose Tissue, Brown/metabolism , Animals , Base Sequence , Blotting, Western , DNA Primers , Gene Expression , Immunohistochemistry , Male , Mice , Mice, Knockout , Obesity/etiology , Obesity/metabolism , Positron-Emission Tomography , Real-Time Polymerase Chain Reaction , Receptors, Prolactin/genetics , Thermogenesis
11.
Mol Endocrinol ; 23(7): 1043-51, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19359342

ABSTRACT

Grb14 belongs to the Grb7 family of molecular adapters and was identified as an inhibitor of insulin signaling. Grb14 binds to activated insulin receptors (IR) and inhibits their catalytic activity. To gain more insight into the Grb14 molecular mechanism of action, we generated various mutants and studied the Grb14-IR interaction using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET) experiments. Biological activity was further analyzed using the Xenopus oocyte model and a functional complementation assay measuring cellular proliferation rate in Grb14 knockout mouse embryonic fibroblasts. These studies identified two important interaction sites, Grb14 L404-IR L1038 and Grb14 R385-IR K1168, involving the IR alphaC-helix and activation loop, respectively. Interestingly, the former involves residues that are likely to be crucial for the specificity of IR binding with regard to other members of the Grb7 family. In addition, mutation of the Grb14-S370 residue suggested that its phosphorylation status controlled the biological activity of the protein. We further demonstrated that insulin-induced Grb14-PDK1 interaction is required in addition to Grb14-IR binding to mediate maximal inhibition of insulin signaling. This study provides important insights into the molecular determinants of Grb14 action by demonstrating that Grb14 regulates insulin action at two levels, through IR binding and by interfering with downstream pathways. Indeed, a precise knowledge of the molecular mechanism of insulin signaling inhibition by Grb14 is a prerequisite for the development of insulin-sensitizing molecules to treat pathophysiological states such as obesity or type 2 diabetes.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Insulin Antagonists , Insulin/metabolism , Adaptor Proteins, Signal Transducing/chemistry , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Amino Acid Motifs/genetics , Amino Acid Motifs/physiology , Animals , COS Cells , Cells, Cultured , Chlorocebus aethiops , Humans , Insulin Antagonists/chemistry , Insulin Antagonists/metabolism , Mice , Mice, Knockout , Protein Binding/genetics , Protein Serine-Threonine Kinases/metabolism , Protein Structure, Tertiary , Pyruvate Dehydrogenase Acetyl-Transferring Kinase , Receptor, Insulin/chemistry , Receptor, Insulin/metabolism , Signal Transduction/genetics , Signal Transduction/physiology , Xenopus
12.
Endocrinology ; 149(6): 3109-17, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18339716

ABSTRACT

Tight control of insulin action in liver is a crucial determinant for the regulation of energy homeostasis. Growth factor receptor-bound protein 14 (Grb14) is a molecular adapter, highly expressed in liver, which binds to the activated insulin receptor and inhibits its tyrosine kinase activity. The physiological role of Grb14 in liver metabolism was unexplored. In this study we used RNA interference to investigate the consequences of Grb14 decrease on insulin-regulated intracellular signaling, and on glucose and lipid metabolism in mouse primary cultured hepatocytes. In Grb14-depleted hepatocytes, insulin-induced phosphorylation of Akt, and of its substrates glycogen synthase kinase 3 and fork-head box protein 1, was increased. These effects on insulin signaling are in agreement with the selective inhibitory effect of Grb14 on the receptor kinase. However, the metabolic and genic effects of insulin were differentially regulated after Grb14 down-regulation. Indeed, the insulin-mediated inhibition of hepatic glucose production and gluconeogenic gene expression was slightly increased. Surprisingly, despite the improved Akt pathway, the induction by insulin of sterol regulatory element binding protein-1c maturation was totally blunted. As a result, in the absence of Grb14, glycogen synthesis as well as glycolytic and lipogenic gene expression were not responsive to the stimulatory effect of insulin. This study provides evidence that Grb14 exerts a dual role on the regulation by insulin of hepatic metabolism. It inhibits insulin receptor catalytic activity, and acts also at a more distal step, i.e. sterol regulatory element binding protein-1c maturation, which effect is predominant under short-term inhibition of Grb14 expression.


Subject(s)
Hepatocytes/physiology , Insulin/pharmacology , Proteins/physiology , Adaptor Proteins, Signal Transducing , Animals , Gene Deletion , Glucose/metabolism , Hepatocytes/drug effects , Kinetics , Lipids/physiology , Liver Glycogen/metabolism , Male , Mice , Mice, Inbred C57BL , Proteins/genetics , RNA, Small Interfering/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sterol Regulatory Element Binding Protein 1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...